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The standard surgical treatment of invasive bladder cancer is the radical cystectomy and pelvic lymph node dissection (PLND).
Up to one-third of patients with invasive bladder cancer have lymph node metastasis. Thus, PLND has important therapeutic and
prognostic beneﬁts. The number of lymph nodes that should be removed and the extent of the PLND are still a controversial issue.
Recently, the trend of PLND increased toward more extended PLND. Several prognostic factors related to PLND were reported
in the literature. In this paper, we will discuss the diﬀerent PLND templates, number of lymph nodes that should be resected,
lymph node density, lymphovascular invasion, tumor burden, extracapsular extension, and the aggregate lymph node metastasis
diameter.
1.Introduction
According to cancer statistic 2010, bladder cancer is the
fourth most common tumor in men in the United States,
the number of new cases diagnosed were estimated to be
70,530 (52,760 men and 17,770 women), leading to 14,680
deaths [1]. In Europe, bladder cancer represents 6.6% and
2.1% of the total cancers and 4.1 % and 1.8% of total deaths
for cancer in men and women, respectively [2].
Radical cystectomy (RC) accompanied by pelvic lymph
node dissection (PLND) is still the gold standard surgical
treatment for muscle invasive bladder cancer. In the past, the
role of PLND was purely diagnostic to rule out lymph nodes
(LN) metastasis; currently, PLND is considered an essential
partofsurgicaltreatmentofbladdercancer.Fourteento30%
of the patients of invasive bladder cancer have LN metastasis
at the time of RC [3, 4]. The incidence of LN metastasis
increased with higher tumor stage. LN-positive disease was
found in 5% patients with superﬁcial bladder tumors and
18% of patients with P2 tumor, 26% of patients with P3a
disease, and 46% of patients with P3b, and 42% of patients
with P4 tumors [3].
It is common knowledge that the patients with LN me-
tastasis have a poor prognosis, Vieweg et al. [5]r e p o r t e do n
140 patients with LN positive, 25.7% were disease-free, and
15.7% surviving beyond 5 years. In another study, the 3-
year survival in patients who underwent RC and PLND with
negative and positive LN was 78.3% and 37.8%, respectively
[6]. Thus, PLND is associated with favorable prognosis and
better cancer control. Four decades ago, many urologists did
not perform PLND with RC [7]. In 1950, Kerr and Colby
noted that the local recurrence rate decreased after cystec-
tomy combined with PLND [8].
In 1973, Dretler et al. [9] reported the value of inclusion
of PLND during RC without increasing the morbidity and
mortality. Skinner [10] suggested that PLND can cure some
patients with metastatic disease, eﬀectively controls pelvic
disease and can make a diﬀerence in survival.
In 1981 Smith and Whitmore [11] reported on one of the
ﬁrst anatomical LN mapping studies in patients undergoing
RC and they suggested the possible therapeutic eﬀect of a
systematic bilateral PLND as a major determinant of patient
survival. Although there is consensus the PLND should be
an integral part of cystectomy; the extension of PLND is not2 Advances in Urology
standardized and the number of LNs that should be removed
has yet to be deﬁned [12].
In this article we will review the therapeutic and prog-
nostic value of PLND, the optimal surgical template, and the
minimum number of nodes to be removed.
2. Lymphatic Drainage of the Bladder and
Templates of PLND
The lymphatic drainage of the bladder consists ofthe visceral
lymphatic plexus inside the submucosa and the muscular
layer, the small intercalated lymph nodes located within the
perivesical fat, pelvic collecting trunks which is medial to the
iliacLNs,regionalpelvicLNs,whichincludetheexternaland
internal iliac, and sacral LNs, lymphatic trunks from the
regional pelvic LNs to the common iliac LNs [13]. The pelvic
LNs are embedded in fat and diﬃcult to be appreciated
during the surgery. The primary drainage sites include ex-
ternal and internal iliac and obturator LNs, secondary drain-
age from the common iliac LNs, and tertiary drainage from
the trigone and posterior bladder wall is to the presacral
nodes [14]. LNs mapping studies in RC shows that the rate
of positive LNs detected decreased gradually from distal to
more proximal sites and the most common site of LN
metastasis were in the obturator and iliac LNs. Positive LNs
were found in the perivesical fat and in the pelvic region
in 22.7% of all patients, in the common iliac nodes in 8%,
in the presacral region in 5.1% and at or above the aortic
bifurcation in 4% [14]. In another study, the distribution of
theLNmetastasisintheexternaliliac,obturator,andinternal
iliac region was 33%, 38%, and 29%, respectively. Metastases
in only one region were found in 33% of patients (13% in
the external iliac LNs, 10% in the obturator LNs, and 10% in
the internal iliac LNs); 50% of all patients had lymph node
metastases in the internal iliac region [15].
Abol-Enein et al. [16] in pathoanatomical study of LN
involvement in patients with bladder cancer, concluded that
the internal iliac and obtur ator LNs (endopelvic region) is
the sentinel region of the lymphatic drainage of bladder
cancer and there are no skipped lesions or isolated nodal
metastasis above the aortic bifurcation. Thus any metastasis
outside the true pelvis occurred only in multinodal disease
and it was always associated with involvement of the obtu-
rator and/or internal iliac nodes. Others reported that single
positive nodes were located outside of the pelvis in 27% of
patients [17]. The diﬀerence between these ﬁnding may be
explainedbythevariationinthenaturalhistoryofthedisease
[16].
Early RC series suggested that it was not necessary to in-
clude the aortocaval lymph nodes in PLND, as a part of the
cystectomy [13, 18]. Others suggested the importance of an
extended PLND to include common iliac LNs to remove all
potential LN metastases [11].
The limits of each surgical template of PLND are not
clearly deﬁned in the urology guidelines. Although the ab-
solute boundaries of the PLND remain a subject of contro-
versy, three categories of PLND are reported in the literature,
limited, standard, and extended. The limited PLND drains
part of the primary drainage and includes only the obturator
a n de x t e r n a li l i a cL N s[ 7].
The standard PLND was deﬁned as a removal of all
nodal tissue of primary and secondary lymphatic drainage of
the bladder and encompasses the common iliac bifurcation
proximally, the genitor-femoral nerve laterally, the circum-
ﬂex caudal iliac vein and lymph node of Cloquet distally, and
the internal iliac vessels posteriorly, including the obturator
fossa. The nodes around the proximal half of the common
iliac artery/aortic bifurcation are spared to avoid injury to
the hypogastric nerves [19].
The boundaries of extended PLND are 1-2cm above the
aortic bifurcation and common iliac vessels proximally (oth-
ers may extend the PLND up to the level of inferior me-
senteric artery), the genitofemoral nerve laterally, the cir-
cumﬂex iliac vein and lymph node of Cloquet distally, the
internal iliac vessels posteriorly, including the obturator
fossa,thepresciaticnodesbilaterally,andthepresacrallymph
nodes over the sacral promontory [20].
Leissner et al. [17] deﬁned three diﬀerent anatomical
levels of metastasis: Level I, included in the standard tem-
plate; Level II, including the aortic bifurcation; Level III,
including the para-aortic and paracaval areas. The authors
noted that, if there is a nodal metastasis at Level I, positive
nodes were also found in 57% and 31% of cases at Levels II
and III, respectively. If positive nodes were found at Level II,
35% of cases were positive at Level III. Positive nodes at Level
III were found only if metastases were present in 9 or more
nodes at Levels I and II.
3. CurrentPracticeof PLND
In 2004, Herr et al. [21] reported on 1091 consecutive RC
performed by 16 experienced surgeons from 4 institutions
between 2000 and 2002. Surgeons performed a standard
PLND in 67% of patients, extended PLND in 13% of pa-
tients, and for various reasons 20% had a limited (9%) or
no node dissection (11%). In analysis of the Surveillance,
Epidemiology and End Results (SEER) data of 3603RC
performed between 1992 and 2003, Hollenbeck et al. [22]
divided the hospitals according to the node count during
cystectomy, low (no patients with ≥ 10LNs removed),
medium(upto20%ofpatientswith ≥10LNsremoved),and
high (greater than 20% of patients with ≥ 10LNs removed).
The authors found that only 0–4 nodes were retrieved in
88.9% and 52.8% of cases in the low and high node count
hospitals, respectively. The percentages of patients who had
≥10LNsremovedwere0%atlowLNcounthospitals,12.7%
at medium LN count hospitals, and 35.3% at high LN count
hospitals. It seems that the majority of cystectomy patients
had ≤4 LNs removed irrespective of the hospital and optimal
PLND is not commonly performed.
The possible reasons for no or limited PNLD during RC
was reported by Koppie et al. [23] who found that patients
with older age and higher comorbidities were less likely to
have PLND, and when PLND was performed, fewer LNs
were evaluated. In another analysis of SEER data, Hellenthal
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(1 or more nodes) decreased nearly 20% per 10-year age
increase. Also the odds increased by a factor of 1.5 in the
tumor stage TisN0M0 to T3N0M0 and decreased in stage
T4N0M0. The same authors concluded that 21% of patients
did not have any LNs sampled at radical cystectomy. This
numberdecreasedfrom37%in 1988 to16%in 2004. During
this period the mean number of LNs removed increased by
2.6 nodes and the percentage of patients undergoing any
form of lymph node dissection increased by an average of
19%. As of 2004, 84% of patients had at least 1LN (and a
meanof13nodes)examinedatcystectomy.Similarly,Koppie
et al. [25] noticed that the number of removed LN was
associated with year of surgery in their series. The mean
number of LNs removed during 1990–1994, 1994–1999, and
2000–2004 was 7.5, 8.6, and 14.7, respectively.
4.Therapeutic andPrognosticValue of PLND
4.1. Extent and Number of Lymph Nodes Removed.
Weing¨ artner et al. [26] assessed the adequate number of LNs
to be removed for achievement of complete and accurate
PLND. Standard PLND was performed on 30 human cadav-
ersand59consecutivepatientswithclinicallyorganconﬁned
prostate cancer during radical retropubic prostatectomy.
T h em e a nn u m b e ro fL N sr e m o v e di nt h ea u t o p s ys e r i e s
and from patients with prostate cancer was 22.7 ± 10.2
and 20.5 ± 6.6, respectively, with many interindividual dif-
ferences. The authors concluded that the threshold of ap-
proximately 20 nodes was suﬃcient. The average number
of nodes removed during the standard and extended PLND
was reported to be 13 (9–18) and 31.5 (14.7–50), respectively
[7].
The number of LNs retrieved during PLND is quite var-
iable and diﬀerent cutoﬀ number of LNs that should be
dissectedwassuggested.Sofarthereisnoconsensusavailable
for the standard number of LNs that should be retrieved in
patients with bladder cancer. The higher number of LNs re-
trieved may reﬂect more complete RC and PLND. Several
studies showed that disease-free survival or recurrence-free
survival improved with more number of nodes retrieved
which was an independent prognostic factor even after ad-
justing for node status, surgical margin, and pT stage [27–
29]. Herr et al. [27] found that the survival rate in the node
negative patients was improved with more number of nodes
removed, which may be attributed to an improved staging,
and possible removal of undetectable micrometastasis. The
authors suggested PLND of at least 9 or more as a minimum
standard provides individual prognostic information.
Others reported on decreased risk of death in patients
whohad10–14lymphnodesremoved.Patientswithlessthan
3LNsretrievedwereatsigniﬁcantlyhigherriskofdeathfrom
bladder cancer than those with greater than 3 [30]. Leissner
et al. [31] found that the extended PLND of ≥ 16LNs
correlated with a higher percentage of patients with docu-
mented nodal metastases. There was a signiﬁcant correlation
between the number of removed LNs and the tumor-free 5-
year survival in patients with pT1, pT2, or pT3 tumors.
Fang et al. [32] reported on 349 patients who underwent
RC and PLND between March 2000 and February 2008.
The authors established an institutional policy mandating at
least 16 LNs be examined in March 2004. Of all, 147 and
202 patients underwent surgery before and after the policy
was implemented, respectively. The median number of LNs
examined increased from 15 in the period before policy im-
plementation to 20 in the 4 years after. Survival rates in-
creased from 41.5% in the 4 years before policy implemen-
tation to 72.3% in the 4 years after. Capitanio et al. [33]
reported on a multicenter study to identify the probability
of ﬁnding one or more positive LNs based on the number
of LNs removed. The authors found that removing 45LNs
yielded a 90% probability. However, removing either 15 or
25LNs indicated probability of 50% and 75%, respectively.
They concluded that removing 25LNs might represent the
lowest threshold for the extent of PLND at RC. Others re-
ported that at least 23 nodes would need to be removed in
order to identify 80% of positive nodes [34].
The number of LNs resected is a surrogate for the extent
of dissection and the quality of RC. Thus it seems to be
diﬃcult to establish a minimum or threshold number of LNs
that should be removed during PLND due to the lack of a
standardized template of PLND. According to Koppie et al.
[25]removing10LNsmayrepresentathoroughLNcleanout
from a limited LN template, or a relatively incomplete dis-
section of LNs from an extended LN template. The authors
concluded that no evidence was found to support a mini-
mumnumberofLNssuﬃcientforoptimizingbladdercancer
outcomes when a limited or extended PLND is performed
during RC. The probability of survival continues to increase
as the number of LNs retrieved increases. Also, the authors
recommended more extended PLND at the time of RC.
Several studies demonstrated that extended PLND de-
crease local recurrence and improve cure rates when it com-
paredtolimitedandstandardPLND[31,35].Dharetal.[36]
reported on a multicenter study comparing the recurrence
patternsandsurvivalof658patientswhounderwentRCwith
either limited or extended PLND. The overall LN-positive
ratewas13%and26%forpatientswithlimitedandextended
PLND, respectively. The 5-year recurrence-free survival was
77% for pT2N0, 57% for pT3N0, and 35% for node-positive
tumors in the extended PLND group versus 67%, 23%, and
7%, respectively, in the limited PLND group ( P<0.0001).
In another study, LN metastases were detected in 38%
and 17% of the extended and limited dissection groups, re-
spectively. There was no signiﬁcant diﬀerence in survival or
time to recurrence between the 2 groups. However, the mul-
tivariate analysis demonstrated signiﬁcantly improved sur-
vival and time to recurrence in the patients with extended
PLND [37].
In addition to its therapeutic beneﬁt, extended PLND
oﬀers more accurate staging compared to a limited/standard
PLND. Dangle et al. [34] found that limited PLND would
have missed 25% of LN-positive patients whereas standard
PLND would have missed 11% of LN positive cases. Others
notedthatlimitedandstandardPLNDwouldhavemissed27
and 10% of LN metastases in patients with a single positive
lymph node, respectively [17]. Seiler et al. [15] found that4 Advances in Urology
PLND that do not include the internal iliac region misses
26% of all pelvic lymph nodes, 29% of metastases, and un-
derstages a substantial number of patients as pN0 (10%).
Although surgical cure is rare in patients with gross nod-
al metastasis (N2-3), the RC with extended PLND can pro-
vide cure in this group of patients. The 10-year disease-free
survival was reported in 24% of patients with surgery alone
and 76% of patients died of disease. Thirty-two percent of
patients with T2 tumors survived versus 9.7% of patients
with stage T3 tumors [38].
4.2. Tumor Burden. The number of positive nodes retrieved
is indicative of the tumor burden and considered as inde-
pendent from the number of nodes removed. The survival
rate is directly correlated with number of LN metastasis. Sev-
eral cut oﬀ number of positive LNs was reported. One of
these studies showed that the survival of patients with pos-
itive nodes was signiﬁcantly better if ≤4p o s i t i v en o d e sw e r e
removed than if there were >4 positive nodes (37% versus
13%) [27]. Improved overall survival was shown in a study
by Lerner et al. [39] when 5 or fewer positive nodes were
detected (40% versus 10%). The mean 3-year survival for
patients with 1, 2–5, and > 5 positive LNs was 58.6%, 31.8%,
and6.8%,respectively[6].Fleischmannetal.[40]foundthat
the Overall 5-year survival was 35% and 17% in patients
with <6a n d≥6 positive LN, respectively. Others showed
that the 10-year recurrence-free survival was signiﬁcantly
better in patients with ≤8 positive nodes than in those with
>8 metastatic nodes (40% versus 10%) [41]. Kassouf et al.
[42] reported that the number of positive nodes was sig-
niﬁcantly associated with recurrence-free survival on univar-
iate analysis (P = 0.04), but lost statistical signiﬁcance on
multivariable model (P = 0.055).
4.3. Lymph Node Density. LN density deﬁned as number of
positive LN divided by the total number of nodes removed
and examined. It included 2 prognostic factors the tumor
burden and the extent of PLND. The most commonly util-
ized LN density cut-point was 20%. The concept of LN den-
sity was introduced and named “ratio-based” lymph node
staging by Herr in 2003 [43]. They found that the 5-year
overall survival decreased from 64% when the ratio was
≤20% down to 8% when it was >20%. The same concept
was later reported under a diﬀerent name (LN density) by
Stein et al. [41] who showed decreased 10-year recurrence-
free survival from 43% when the LN density was ≤20% to
17% when it was >20%. Others reported that the LN density
showed some predictive ability, especially at a cutoﬀ of 50%
[30].
Kassouf et al. [44] compared nodal status and LN den-
sity in a multivariate model. For powerful LN density, a
minimum number of 9 nodes need to be resected. The
authors found that only LN density >20% predicted de-
creased disease-speciﬁc survival and remained prognostic in
patients who received adjuvant chemotherapy. Also the LN
densityissuperiortotumor-node-metastasis(TNM)classiﬁ-
cationfornodalstatusinpredictingdisease-speciﬁcforsusvii
patients with LN-positive disease. This study and others
support the use of LN density in the pathologic staging of
node-positive bladder cancer [45].
Although Abdel-Latif et al. [6] found that both number
of positive nodes (1 versus 2–5 versus >5) and LN density
(<10 versus 10–20 versus >20%) showed statistical signif-
icance on univariate analyses, only the number of posi-
tive nodes remained signiﬁcant on multivariate modeling.
Wright et al. [28] found statistically signiﬁcant correlation
between the number of positive nodes (1 versus 2 versus 3
versus >3) and lymph node density, and disease-speciﬁc and
overall survival.
4.4. Lymphovascular Invasion. Lymphovascular invasion
(LVI) means the presence of tumor cells in the endothelium-
lined space. In a recent longitudinal evaluation of the
prognostic value of LVI, Resnick et al. [46] found that 12.3%
of patients had LVI at transurethral resection of the bladder
tumour (TURBT) compared to 33.1% at RC. The risk of
nodaldiseasewashigherinthosepatientswithLVIatTURBT
than in those with no evidence of LVI at TURBT (48.3%
versus 25.0%, P<0.001). The authors concluded that the
LVIhasausefulprognosticvalueandshouldbeincorporated
into clinical decision making, particularly for RC in patients
with superﬁcial bladder carcinoma and the need for neoad-
juvant chemotherapy.
Quek et al. [47] noted that the LVI is an important and
independent prognostic variable in patients with invasive
bladder cancer. It was signiﬁcantly correlated with positive
surgical margins, high pathological stages, older patients,
and sex (female). Ten-year recurrence-free survival in pa-
tients without LVI was 74% compared with 42% in those
with LVI (P<0.0001). Similarly 10-year overall survival was
43% in patients without LVI compared with 18% in those
with LVI (P<0.0001).
In another study, LVI was not signiﬁcantly associated
with age or sex, but was signiﬁcantly associated with high
pathological grade (P = 0.028), stage (P<0.001), and node
metastasis (P<0.001). At the multivariate analysis, LVI was
an independently signiﬁcant prognostic factor for disease-
speciﬁc survival [48, 49]. Others noted that the LVI in node-
negative patients is an adverse prognostic factor on univar-
iate analysis of disease-speciﬁc survival, but not an indepen-
dent prognostic factor on multivariate analysis [50].
S h a r i a te ta l .[ 51] reported on international validation of
the prognostic value of LVI in 4257 patients treated with RC.
In analysis, LVI was associated with both disease recurrence
(hazard ratio 1.43, P<0.001) and cancer-speciﬁc mortality
(1.45, P<0.001). In patients with negative LNs, LVI was in-
dependently associated with and improved the predictive
accuracy of the standard predictors for recurrence (hazard
ratio 1.68, P<0.001; +2.3%) and cancer-speciﬁc mortality
(1.70, P<0.001; +2.4%). The authors concluded that the
LVI should be included in the staging of bladder cancer.
4.5. Extracapsular Extension of the Lymph Node (ECE). Cur-
rently, there are a few reports in the literature investigating
the prognostic value of ECE of LN metastasis. Perforation
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indicate aggressive behavior of the tumor. Fleischmann et al.
[40] found the ECE was observed in 58% of patients and in
the multivariate analysis for recurrence-free survival, ECE of
LN metastases was the strongest prognostic factor (P =
.019) of recurrence-free and overall survival. In contrast,
Kassouf et al. [52] suggests that ECE is not an independ-
entprognosticfactorforoverallsurvival,disease-speciﬁcsur-
vival, and recurrence-free survival in patients with positive
LNs.
4.6. The Aggregate LN Metastasis Diameter (ALNMD). Some
studies suggested that the size of the largest LN metastasis
and/or the aggregate LN metastasis diameter (ALNMD) may
provide prognostic information about the extent of LN
metastasis, and the patients’ survival. Mills et al. [53]n o t e d
that there is a signiﬁcant association between the diameter of
the largest LN metastasis and overall survival. Very recently,
Stephenson et al. [54] reported on 134 positive LN patients
treated with RC and minimum standard PLND. The median
overall survival was 26 months for patients with ALNMD
≤20mm versus 11 months for those with ALNMD >20mm
(P = .001). The authors concluded that ALNMD is a sig-
niﬁcant predictor of recurrence-free survival and overall
survival and may provide a useful parameter to be included
in the TNM-staging systems.
5. Role of the Pathologist inLNs Assessment
The accurate assessment of LN specimen depends on the
carful work of the pathologist when searching the specimen
forLNsandthewayofspecimensubmissionforpathological
examination. Bochner et al. [55] found that individual LN
specimen yielded more LNs compared to en bloc specimen
in standard PLND (8.5 versus 2.4 LNs, P = 0.003) and ex-
tended PLND (36.5 versus 22.6 LNs, P = 0.02). This result
conﬁrmed by Stein et al. [56] who suggests 13 separate nodal
packetstoincreasethetotalnumberoflymphnodesremoved
compared with en bloc submission.
The traditional method of detecting the LNs by section-
ing and palpating the specimen may fail to detect the very
small LNs. Koren et al. [57]d e s c r i b e dan e wL y m p h - n o d e
revealing solution (LNRS) for detecting LNs in PLND spec-
imen. The solution comprised 95% ethanol, diethyl ether,
glacial acetic acid, and buﬀered formalin and used to de-
grease the tissue. The authors found that using the LNRS
doubled the number of LNs yield, detected signiﬁcantly
smaller LNs, and improved nodal staging.
Herr et el. [58] reporting on pathologic evaluation of RC
specimens, found that in 18% of patients, pathologists did
not mention either the presence or the number of LNs.
Standardized pathologic evaluation and reporting of RC and
LN specimens is critical in cancer staging and design of clin-
ical trials.
6.Laparoscopic/Robot-AssistedPLND
Laparoscopic PLND for prostate cancer was initially de-
scribed by Schuessler et al. [59]. The laparoscopic surgery is
minimally invasive with advantages of decreased blood loss,
shorter hospital stay, and early recovery. Several reports
showed that there is no signiﬁcant diﬀerence in the intraop-
erative complications and the number of LNs removed by
laparoscopic approach when compared with open surgery
[60, 61].
Introduction of robot-assisted laparoscopic surgery add-
ed more ﬁeld magniﬁcation with 3-dimensional vision and
simulates the movements of the surgeon’s wrist. Guru et al.
[62]evaluatedthenumberofLNsyieldduringrobot-assisted
RC and found that the mean operative time for PLND is 44
minutes (19–85) and the mean number of LNs removed was
18 (6–43).
It seems likely that the robot-assisted PLND can produce
comparableresultstoopensurgery;however,morestudiesof
the techniques and learning curve are still needed [63].
7.MorbidityandMortalityof PLND
Although, RC is major surgery with potential high rates of
complications, extended PLND does not increas morbidity
or mortality. There is no signiﬁcant diﬀerence between LN-
positive and -negative patients in terms of postoperative
complications [41]. In a study comparing extended PLND
(up to the aortic bifurcation) to a more limited PLND,
similar mortality rates were observed in the 2 groups [35].
Similarly, Leissner et al. [31] observed that the postoperative
c o m p l i c a t i o n ss u c ha sl y m p h o c e l ea n dl y m p h o e d e m aw e r e
similar in patients with <16lymph nodes removed and pa-
tients with >16 nodes removed (2% versus1%). Although
the extended PLND increased the operative duration by 63
minutes, the limited and extended PLND patients did not
diﬀer signiﬁcantly in terms of perioperative mortality and
morbidity. Complications requiring surgical interventions
occurred in 9% patients in limited PLND and 11% in ex-
tended PLND group (P = 0.28) [64].
8. Conclusion
PLND is an essential part of the surgical treatment of blad-
der cancer for its staging, curative, and prognostic role. The
beneﬁts of extended PLND were demonstrated in several
studies with no signiﬁcant diﬀerence in morbidity and mor-
tality when compared to standard PLND. Despite the grow-
ing evidence that support the extended PLND up to the in-
ferior mesenteric artery, the optimum PLND template is still
controversial and its boundaries and the number of retrieved
LNs have not yet been deﬁned. Well-designed randomized
controlled trials comparing standard to extended PLND in
RC patients is still needed. The extent of PLND and the
number of positive LNs are well-established risk factors;
however, the cut oﬀ n u m b e ro fp o s i t i v eL N si ss t i l lt ob e
deﬁned. Several reports suggested that LVI and LN density
should be included in the pathologic staging of bladder
cancer. The prognostic value of ECE and ALNMD still need
more investigations.6 Advances in Urology
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